{"id":287781,"date":"2026-10-05T16:55:05","date_gmt":"2026-10-05T11:25:05","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=287781"},"modified":"2026-10-05T16:55:05","modified_gmt":"2026-10-05T11:25:05","slug":"sobha-target-price-emkay-buy-rs-1900-despite-18-percent-fall-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sobha-target-price-emkay-buy-rs-1900-despite-18-percent-fall-2\/","title":{"rendered":"Sobha Target Price Rs 1,900: Why Emkay Stays Positive Despite an 18% YTD Fall, With 59% Upside, a Rs 1,571 NAV, SOTP Valuation, the Q2 Business Update and the Risks"},"content":{"rendered":"

Emkay Buy, Sobha target price Rs 1,900 (59% upside). NAV Rs 1,571. Stock down 18% YTD. H1 FY27 pre-sales Rs 5,862 cr; FY27E Rs 10,600 cr.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Sobha target price is Rs 1,900 at Emkay Research, which retains a Buy and sees about 59% upside from a stock that is down 18% so far in 2026, around Rs 1,195 by implication. The target is a 21% premium to Emkay’s NAV estimate of Rs 1,571 per share, and the stock trades at roughly a 24% discount to that NAV, according to my arithmetic. Emkay’s case rests on record H1 FY27 pre-sales of Rs 5,862 crore, a FY27 pre-sales estimate of about Rs 10,600 crore and a sharp margin recovery from the second half, with FY27 EBITDA expected to rise about 147.5%. The risks are lumpy launches, a 40% fall in Q2 sales from Q1, a market that has de-rated realty and a target that depends on delivery in the second half.<\/p>\n<\/p><\/div>\n

Sobha target price is back in focus after Emkay Global Financial Services reiterated its Buy on the Bengaluru-based developer despite an 18% fall in the stock this year. The brokerage’s target of Rs 1,900 implies about 59% upside, and the call follows Sobha’s Q2 FY27 business update of 2 October, which showed record first-half pre-sales.<\/p>\n

If you are searching for the Sobha target price and the Emkay view, this article covers why the Emkay Buy stays positive, the Sobha NAV and sum of the parts valuation, the Sobha Q2 business update, the margin recovery and earnings inflection, the launch pipeline and net cash balance sheet, why the stock has fallen 18%, reference levels and the risks. Emkay’s figures are from its research note, and the current price is implied from the reported upside, so recheck live data.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n